We Guide Drug Development

01. CORE COMPETENCE

We are an integrated development company with strong expertise in identifying and executing strategies for drug development that can leverage development resources through collaborative arrangements with partners in our global network.

SWOT: Strengths, Weaknesses, Opportunities, and Threats

PROJECTEVALUATION &LICENSING CANCER MARKETSWOT ANALYSIS DEVELOPMENTSTRATEGY &EXECUTION SCALE UP &MANUFACTURINGDESIGN COOPERATION WITHONCOLOGY EXPERTS CLINICALTRIAL DESIGN &EXECUTION COMPLIANCE WITHGLOGAL REGULATIONS FINANCIALRISK MANAGEMENT
PROJECTEVALUATION &LICENSING CANCER MARKETSWOT ANALYSIS DEVELOPMENTSTRATEGY &EXECUTION SCALE UP &MANUFACTURINGDESIGN COOPERATIONWITH ONCOLOGYEXPERTS CLINICALTRIAL DESIGN &EXECUTION COMPLIANCE WITHGLOGALREGULATIONS FINANCIALRISK MANAGEMENT
PROJECTEVALUATION&LICENSING CANCERMARKETSWOTANALYSIS DEVELOP.STRATEGY&EXECUTION SCALE UP&MANUFACT.DESIGN COOPERATIONWITHONCOLOGYEXPERTS CLINICALTRIAL DESIGN&EXECUTION COMPLIANCEWITHGLOGALREGULATIONS FINANCIALRISKMANAGEMENT
02. THE “NRDO“ MODEL

PharmaEngine has adapted the No Research, Development Only model (NRDO) as well as Networked Pharma Model (out-sourcing) for new drug development. We license in drug candidates for drug development, taking them through various stages ranging from preclinical to clinical and further out-licensing.

CRO: Contract Research Organization, CMO: Contract Manufacture Organization

IN-LICENSEPARTNERS OUT-LICENSEPARTNERS CROPARTNERS CMOPARTNERS PRE-CLINICAL TARGET LEAD PRE-CLINICAL PHASES I II III APPROVAL SALES
IN-LICENSEPARTNERS OUT-LICENSEPARTNERS CROPARTNERS CMOPARTNERS PHASES I II III APPROVAL PHASES I II III APPROVAL SALES PRE-CLINICAL TARGET LEAD
IN-LICENSEPARTNERS OUT-LICENSEPARTNERS CROPARTNERS CMOPARTNERS TARGET LEAD PRE-CLINICAL P I II III APPROVAL SALES

Ask Us Anything About Our Business Model

Your Name

Your Enterprise

Your Email

Your Interest